Cardiomyopathy Trial, Recruiting NCT05632432 Sponsor: Hospital District of Helsinki and Uusimaa Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT05632432
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have agreed to take part and given your written consent
  • A heart scan (echocardiogram) has shown that your heart's pumping strength is between 15% and 40% (lower than normal)
  • You have been diagnosed with heart failure with symptoms ranging from mild (noticeable during everyday activity) to severe (present even at rest)

Who may not be able to join:

  • Your heart failure is caused by a blockage in the main outlet of the heart's left pumping chamber
  • You have had a heart attack in the last 30 days
  • You have a history of dangerous, potentially recurring abnormal heart rhythms, have been resuscitated, or have an implanted heart device to correct abnormal rhythms (ICD)
  • You have had a stroke or another serious disabling condition within the last 3 months
  • You have severe heart valve disease or are already scheduled for heart valve surgery
  • Your kidneys are not working well enough (confirm with trial site)
  • You have another serious illness that is expected to shorten your life
  • You are unable to have a coronary angiogram (a heart X-ray using dye) or a specific type of heart MRI scan for any reason (confirm with trial site)
  • You are currently taking part in another clinical trial
  • After your medications have been fully adjusted, a special heart MRI shows no scar tissue on the heart, or your heart pumping strength has recovered to 50% or above
  • The special heart MRI required before surgery was not completed in time before your scheduled operation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antti Nykänen, Docent, Hospital District of Helsinki and Uusimaa

Phone: 050 427 0625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hospital District of Helsinki and Uusimaa
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
31 January 2026

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Change in the amount of myocardial scar tissue; Change in plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov